Displaying drugs 1501 - 1525 of 2256 in total
EGT-301
EGT-301 is a gene therapy being investigated for Hunter Syndrome. It consists of an adeno-associated viral vector serotype 9 (AAV9) containing the human Iduronate-2-sulfatase (I2S) transgene designed to restore I2S functional deficiency in patients with Hunter syndrome.
Investigational
Matched Description: … It consists of an adeno-associated viral vector serotype 9 (AAV9) containing the human Iduronate-2-sulfatase …
CRA_10991
Experimental
CRA_10762
Experimental
RB106
Experimental
CRA_10972
Experimental
CRA_10656
Experimental
TG-100801
TG100801 is a topically applied kinase inhibitor in macular degeneration patients. It is administered noninvasively as an eye drop and is designed to suppress VEGF mediated leakage and additional kinase targets associated with inflammation, edema, and angiogenesis which are the pathological hallmarks of AMD and other back of the eye...
Investigational
KB109
KB109 is a prebiotic to feed healthy bacteria for them to to outcompete multi-drug resistance organisms.
Investigational
P-BCMA-101
P-BCMA-101 is an autologous CAR-T therapy developed using Poseida’s piggyBac platform technology.
Investigational
AP103
AP103 is a non-viral gene therapy that uses a delivery vector, HPAE (Highly Branched Poly β-Amino Ester), to deliver the correct collagen VII gene into skin cells.
Investigational
INBRX-101
INBRX-101 is a recombinant human alpha-1 antitrypsin (AAT)-Fc fusion protein.
Investigational
Prezatide
Prezatide is a tripeptide consisting of glycine, histidine, and lysine which readily forms a complex with copper ions . Prezatide is used in cosmetic products for the skin and hair. It is known to aid wound healing and its potential applications in chronic obstructive pulmonary disease and metastatic colon cancer...
Experimental
Skf 107457
Experimental
ILY101
ILY101 is a metal-free, non-absorbed polymeric drug designed for the selective binding and removal of phosphate anions from the gastrointestinal tract. ILY101 is being developed for the treatment of hyperphosphatemia in CKD patients on dialysis and works by reducing the systemic absorption of dietary phosphate. ILY101 is designed to allow...
Investigational
ADL 10-0101
ADL 10-0101 is a peripheral kappa opioid agonist analgesic product candidate. Preclinical trials of ADL 10-0101 have suggested that the compound may be effective for the treatment of inflammatory pain, itch and visceral pain. Because ADL 10-0101 does not cross the blood-brain barrier and enter the brain when administered at...
Investigational
Matched Name: … ADL 10-0101 …
Matched Description: … ADL 10-0101 is a peripheral kappa opioid agonist analgesic product candidate. ... Preclinical trials of ADL 10-0101 have suggested that the compound may be effective for the treatment ... Because ADL 10-0101 does not cross the blood-brain barrier and enter the brain when administered at therapeutic …
Matched Description: … ADL 10-0101 is a peripheral kappa opioid agonist analgesic product candidate. ... Preclinical trials of ADL 10-0101 have suggested that the compound may be effective for the treatment ... Because ADL 10-0101 does not cross the blood-brain barrier and enter the brain when administered at therapeutic …
AEOL-10150
AEOL 10150 is developed by Aeolus as a therapeutic agents based on its proprietary small molecule catalytic antioxidants.
Investigational
PA-1050040
PA1050040, a second generation HIV-1 maturation inhibitor, is a chemical analog of Bevirimat (BVM). It inhibits virus replication by the same mechanism of action as BVM.
Investigational
FF-10101-01
FF-10101-01 is under investigation in clinical trial NCT03194685 (Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia).
Investigational
CXD101
CXD101 is under investigation in clinical trial NCT03873025 (A Study of CXD101 in Combination With Pembrolizumab for Relapsed or Refractory Diffuse Large B-cell Lymphoma).
Investigational
DSP107
DSP107 is a bi-functional, trimeric, fusion protein composed of sequences from the extracellular domain of SIRPα and 4-1BBL.
Investigational
SIS-101-ADO
SIS-101-ADO is a siRNA therapeutic under investigation for the treatment of Autosomal Dominant Osteopetrosis Type 2 (ADO2).
Investigational
Displaying drugs 1501 - 1525 of 2256 in total